Mitchell Young Williams Acquires 51,511 Shares of Biosig Technologies (NASDAQ:STEX) Stock

Biosig Technologies, Inc. (NASDAQ:STEX) CIO Mitchell Young Williams acquired 51,511 shares of the stock in a transaction that occurred on Friday, January 23rd. The stock was purchased at an average price of $3.03 per share, for a total transaction of $156,078.33. Following the completion of the acquisition, the executive owned 1,051,511 shares in the company, valued at $3,186,078.33. The trade was a 5.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Biosig Technologies Trading Up 7.4%

Shares of NASDAQ:STEX opened at $3.65 on Wednesday. Biosig Technologies, Inc. has a 52-week low of $0.40 and a 52-week high of $14.11.

Trending Headlines about Biosig Technologies

Here are the key news stories impacting Biosig Technologies this week:

• Positive Sentiment: Major shareholder Frank Giustra bought 1,000,000 shares at $3.00 (≈$3.0M), increasing his direct stake to 1,178,205 shares — a large, confidence-signaling purchase disclosed to the SEC. SEC Filing
• Positive Sentiment: CIO Mitchell Young Williams acquired 51,511 shares at ~$3.03, raising his holdings to ~1,051,511 shares — another insider buy that supports management confidence. SEC Filing
• Positive Sentiment: Director Morgan Lee Lekstrom executed multiple purchases (including 41,000 and 23,000-share transactions at ~\$3.13–\$3.30), materially increasing her stake — another insider buy pattern reinforcing insider conviction. SEC Filing
• Neutral Sentiment: Press releases show closings of public offerings tied to the STEX ticker (announcements reporting $35M and $40.25M gross proceeds). If these refer to the same issuer, proceeds increase liquidity but also imply share issuance/dilution — impact depends on use of proceeds and whether this is the same corporate entity. Globe Newswire
• Negative Sentiment: Weiss Ratings initiated coverage with a “sell (d-)” rating, and MarketBeat shows an average analyst view of “Sell” — negative third‑party sentiment that can cap upside despite insider buying. Weiss Ratings

Analyst Ratings Changes

Separately, Weiss Ratings initiated coverage on Biosig Technologies in a research report on Friday. They issued a “sell (d-)” rating for the company. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.